Preleukemia clinical trials
The registry lists 1,320 studies for Preleukemia across more than 10 countries. 57 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-08-17.
Status
- Completed
- 821
- Terminated
- 234
- Status unknown
- 105
- Withdrawn
- 66
- Recruiting
- 43
- Active, not recruiting
- 25
Phase
- Phase 2
- 695
- Phase 1
- 472
- Phase 3
- 104
- Phase 4
- 21
- Early Phase 1
- 10
Where
- United States
- 903
- France
- 125
- Germany
- 104
- Italy
- 87
- Canada
- 64
- Spain
- 64
Who runs them
M.D. Anderson Cancer Center (101) · Fred Hutchinson Cancer Center (79) · National Cancer Institute (NCI) (52) · Celgene (35) · Memorial Sloan Kettering Cancer Center (29) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (23) · Groupe Francophone des Myelodysplasies (20) · National Heart, Lung, and Blood Institute (NHLBI) (19)
Studies
Recruiting first, then most recently updated. Showing 50 of 1,320 — search for more.
- Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeRecruitingNCT07216443Phase 21 country
- A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic SyndromeRecruitingNCT06501196Phase 11 country
- Oral-ATO for TP53-mutated Myeloid MalignanciesRecruitingNCT06778187Phase 21 country
- KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT ChildrenEnrolling by invitationNCT02646839Phase 21 country
- Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)RecruitingNCT063799451 country
- Study of REM-422 in Patients With AML or Higher Risk MDSRecruitingNCT06297941Phase 12 countries
- AZA+Lus VS AZA Monotherapy in HR-MDSNot yet recruitingNCT06927232Phase 3
- Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical TransplantationRecruitingNCT06892223Phase 21 country
- Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic MalignanciesRecruitingNCT06886425Not applicable1 country
- Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)RecruitingNCT05924074Not applicable1 country
- Characterization of the Mechanisms of Resistance to AzacitidineRecruitingNCT012102742 countries
- A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic SyndromesRecruitingNCT06196203Phase 22 countries
- Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic SyndromeEnrolling by invitationNCT05674539Phase 31 country
- First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult PatientsRecruitingNCT05601726Phase 1/21 country
- Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic SyndromeRecruitingNCT067645111 country
- Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TDRecruitingNCT05924100Phase 21 country
- A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemiaRecruitingNCT060738601 country
- Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS PatientsRecruitingNCT04587856Not applicable1 country
- A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.RecruitingNCT04275518Phase 11 country
- Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune NeutropeniaRecruitingNCT059317181 country
- VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDSRecruitingNCT06471946Phase 1/21 country
- Transfusion in Lower Risk MDS Patients: Predictors of Adequacy of Transfusion and Quality of Life in Lower Risk MDSRecruitingNCT066145951 country
- A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic SyndromesNot yet recruitingNCT06594965Phase 21 country
- Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic SyndromeRecruitingNCT059024161 country
- TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaNot yet recruitingNCT06598969Phase 21 country
- TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.Not yet recruitingNCT06602323Phase 2
- A Clinical Trial of TQB3455 Tablets in Patients With Hematological MalignanciesRecruitingNCT06550713Phase 11 country
- Sorafenib Relapase Prophylaxis After HCT With PTBCy RegimenRecruitingNCT06532084Phase 21 country
- Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary InvolvementRecruitingNCT061116121 country
- Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic SyndromesRecruitingNCT036212411 country
- ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AMLNot yet recruitingNCT06463327Phase 1
- Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDSRecruitingNCT06247917Phase 21 country
- A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT04243785Phase 11 country
- CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDSRecruitingNCT03291444Phase 11 country
- Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: Protocol for a Diagnostic Accuracy StudyRecruitingNCT051754691 country
- The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic SyndromesRecruitingNCT05925504Phase 21 country
- Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDSNot yet recruitingNCT06050941Phase 2
- Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDSRecruitingNCT06046313Phase 21 country
- A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M ScoreNot yet recruitingNCT06279338Not applicable
- A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDSRecruitingNCT04358393Phase 1/21 country
- Role of BMP Pathway in MDS ProgressionNot yet recruitingNCT061759231 country
- A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDSRecruitingNCT05788679Phase 21 country
- Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDSRecruitingNCT06109064Phase 21 country
- Repurposed Drugs to Improve Haematological Responses in Myelodysplastic SyndromesRecruitingNCT04997811Phase 21 country
- Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RSNot yet recruitingNCT06006949Phase 41 country
- Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMMLRecruitingNCT05970822Phase 11 country
- Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell TransplantationRecruitingNCT05005299Phase 11 country
- A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeRecruitingNCT05140811Phase 1/21 country
- Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCTRecruitingNCT05823714Phase 21 country
- Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAMLRecruitingNCT05584761Phase 1/21 country